Watch for Phase 2b topline data in November 2026 — positive readout could validate Halneuron® and offset dilution concerns. The insider investment reduces near-term financing risk but does not eliminate the binary catalyst risk from the upcoming trial.
Price Chart
Executive Summary
Dogwood Therapeutics announced a $5M private placement from its largest shareholder, CK Life Sciences, at $1.22/share (4.1M shares, no warrants). Proceeds extend runway through March 2027 and fund Phase 3 prep for Halneuron® CINP, with topline Phase 2b data expected November 2026. The investment signals insider confidence but dilutes existing holders by ~15% at a price near the current stock.
Key Financial Metrics
Key Facts
- $5M private placement from largest shareholder CK Life Sciences at $1.22/share
- 4,098,360 new shares issued, no warrants or derivatives
- Expected close on or before October 29, 2026
- Proceeds extend cash runway through March 2027
- Topline Phase 2b data for Halneuron® in CINP expected November 2026
- Halneuron® has FDA Fast Track designation for CINP
Financial Impact
$5M investment at $1.22/share; dilution of ~4.1M shares (est. ~15% of pre-deal outstanding based on typical micro-cap structure)
Risk Factors
- Phase 2b data failure would severely impair stock given single-asset focus
- Dilution of ~15% from this placement at a price near market
- Cash runway only through March 2027 — additional financing likely needed if Phase 3 proceeds
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383440 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13D/A | $1.11 | awaiting T+60 | — | $1.16 (+4.50%) |
Oct 21, 2026 6d ago | SC 13D/A | $1.12 | awaiting T+60 | — | $1.16 (+3.57%) |
Oct 19, 2026 8d ago | 8-K | $1.21 | awaiting T+60 | — | $1.16 (−4.13%) |
Oct 19, 2026 8d ago | Press Release | $1.21 | awaiting T+60 | — | $1.16 (−4.13%) |
Aug 13, 2026 10w ago | 8-K | $1.98 | awaiting T+60 | — | $1.16 (+41.41%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.16 (−31.76%) |
May 14, 2026 23w ago | 8-K | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.16 (−41.41%) |
May 14, 2026 23w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.16 (−41.41%) |
Apr 15, 2026 27w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.16 (−32.16%) |
Mar 18, 2026 31w ago | Press Release | $2.97 $1.57 | ▼ −47.14% | ▼ −58.66% | $1.16 (−60.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers